

Fig. 6


НеГа

nsos


**257RDB** 


181RDB


MCF-Adr



t<sub>F</sub>







30 40 ng/ml 19 Control: No daunorubicin 30 10

Fig. 10

daunorubicin:

daunorubicin: 40 ng/ml Control: No daunorubicin 30

Fig. 11








Fig. 13



Otsia dalsa otsia dalah ek Fig. 15 10000 1000000 10000000000 100000000 Im/u19







5 pfu Xvir03 20 pfu Ad312 not infected

Fig. 18B


after incubation with 5µM Irinotecan for U373 cells infected with 10 pfu dl520/cell

**■** Ad DNA 24 hours Fig. 19

Southern Blot Analysis

U373 cells infected with 10 pfu dl520/cell after incubation for 24 hours with


increasing concentrations of Trichostatin Fig. 20



Southern Blot Analysis


Fig. 21

after incubation with Trichostatin for 24 hours FACS analysis: CAR expression of U373 cells




## Oncolytic effect of d1520 in U373 cells in combination with Irinotecan and Trichostatin

Fig. 22



BfrI – cleavage site = 3534 bp  $3^{\circ}$ UTR = 3507 - 4107 bp ORF = 2019 - 3506 bpE1B55k region: Fig. 23



## Fig. 24

gtectgecegeaaetetaetaeettgaeetaegagaeegtgtetggaaegeeg ggattgtgactgactttgctttcctgagcccgcttgcaagcagtgcagcttcccgt ccgggaacttaatgtcgtttctcagcagctgttggatctgcgccagcaggtttctg gtgggggtcttatgtattttgtatctgttttgcagcagccgccgccatgagc ttggagactgcagcctccgccgcttcagccgctgcagccaccgccgcg accaactcgtttgatggaagcattgtgagctcatatttgacaacgcgcatgcccc catgggccggggtgcgtcagaatgtgatgggctccagcattgatggtcgcccc tcatccgcccgcgatgacaagttgacggctcttttggcacaattggattctttgac 5'tgaggtactgaaatgtgtgggcgtggcttaagggtgggaaagaatatatag actetgtttggatttggatcaagcaagtgtettgetgtetttatttaggggttttge